The effect of itazigrel and aspirin on the mucosa of the esophagus, stomach, and duodenum of normal subjects.
The effects of aspirin, itazigrel (U-53,059; a new antiplatelet drug), and placebo on the mucosa of the esophagus, stomach, and duodenum were evaluated in this double-blind, randomized, placebo-controlled study. Six normal male subjects were included in each of five treatment groups: aspirin (325 mg each morning for five doses), aspirin (325 mg tid for 12 doses), itazigrel (25 mg each morning for five doses), itazigrel (50 mg tid for 12 doses), and placebo. Aspirin and itazigrel, at all doses investigated, significantly inhibited ex vivo, ionophore (A23187)-stimulated thromboxane B2 synthesis. Collagen-induced platelet aggregation was significantly inhibited on day 3 (P = .021) and day 5 (P = .002) in both aspirin and itazigrel groups as compared with placebo. Upper gastrointestinal endoscopy was performed before the first dose of drug (day 1) and two hours after the last dose (day 5) for each subject. A rating scale was used to score the amount of mucosal damage. The baseline (day 1) endoscopic scores revealed no significant differences between groups. On day 5, neither placebo nor itazigrel treatment groups showed any significant change compared with baseline. On day 5, both aspirin groups had significantly (P less than .001) more mucosal damage than the placebo group and either itazigrel group. It is concluded that in this relatively acute study, at doses that produce comparable inhibition of platelet aggregation and platelet cyclo-oxygenase, itazigrel was superior to aspirin in terms of toxicity to the upper gastrointestinal tract.
Kalamazoo Clinical Investigational Complex, Michigan.
D M
DM
Demke
J R
JR
Luderer
L K
LK
Wakefield
A R
AR
Euler
R D
RD
Brouwer
C M
CM
Metzler
D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000009:adverse effects*; D004311:Double-Blind Method; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009061:Mouth Mucosa / Q000187:drug effects* / Q000473:pathology; D010974:Platelet Aggregation / Q000187:drug effects; D011897:Random Allocation; D013844:Thiazoles / Q000009:adverse effects*
D013844:Thiazoles; C035025:itazigrel; D001241:Aspirin